hormone, and luteinising hormone that we found support the concept that cyclical oedema is due to a generalised hypothalamic disturbance producing the somatic and psychological features of the condition. Alternatively, there may be an undefined peripheral factor with secondary hormonal changes that are only markers for the condition. Once an abnormality in the hypothalamic-pituitary axis has been identified the effect of diuretics, dopamine agonists, and centrally acting antidepressant drugs on this abnormality should be determined in the hope that a more effective treatment may be developed. In addition, the test using thyrotrophin releasing hormone and luteinising hormone releasing hormone may enable a more precise and objective diagnosis to be made in this common and distressing disorder.
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We are grateful to Mrs J Holt, Mr There have, however, been no observations on pancreatic lipase activity in sera of these patients. We therefore undertook a study to examine whether the activity of this enzyme is altered in cystic fibrosis.
Patients and methods
Blood samples were collected from 23 patients with known cystic fibrosis (age range 12 to 38 years) with sweat sodium and chloride concentrations greater than 70 mmol(mEq)/l. The serum was separated and stored at -20°C.
Serum was thawed on the day of the assay, and the assays for immunoreactive trypsin and pancreatic lipase were undertaken on the same day to avoid repeated freezing and thawing of sera. Immunoreactive trypsin was measured by a specific radioimmunoassay (Hoechst kit) as described before.2 Pancreatic lipase activity was measured by a turbidimetric method which uses a triolein suspension as substrate and a purified colipase to render the assay specific for the pancreatic enzyme. 4 The reagents for this assay were obtained from Boehringer, and the assay was performed on the Abbott bichromatic analyser ABA 100 at 300C. 4 
Results
The distribution of serum immunoreactive trypsin concentrations and pancreatic lipase activities was non-parametric and is hence expressed as medians with ranges. The statistical comparisons were carried out by Mann-Whitney U test and x2 test.
The median serum pancreatic lipase activity in patients with cystic fibrosis (13 U/l; range 0-588) was significantly lower (p < 0 0001) than that in controls (median 125; range 25-210 U/l; see figure) . The median immunoreactive trypsin concentration was 0 slg/l (range 0-1010), which was also significantly lower (p <00001) than that in controls. Serum pancreatic lipase activity and immunoreactive trypsin concentrations were significantly correlated (r = 096, p < 0 0001). The prevalance of subnormal pancreatic lipase activity (19 patients had activity of less than 50 U/1) and subnormal immunoreactive trypsin concentration (19 patients had concentration less than 140 ,ug/l) was considerably greater in patients with cystic fibrosis than in controls (p <0001). Three patients who had greatly raised lipase activity also had raised concentration of immunoreactive trypsin. Only one patient had both immunoreactive trypsin concentration and pancreatic lipase activity within the normal range.
Two of the three patients with raised lipase activity and raised immunoreactive trypsin concentration did not have steatorrhoea (foecal fat content of less than 5 g in 24 h); the third had steatorrhoea and had to be given pancreatic enzyme supplements.
Discussion
Our results show that serum pancreatic lipase activity is considerably changed in cystic fibrosis. The activities were abnormal in 22 out of 23 patients studied, and a similar prevalence was found for immunoreactive trypsin, as previously reported in patients over the age of 12 years.2 As in the previous study, we found that some patients had supranormal lipase concentrations; in each case immunoreactive trypsin concentration was also high.
The only patient with a normal lipase activity and two with supranormal lipase activity had no evidence of malabsorption. One patient with malabsorption, however, had raised lipase and immunoreactive trypsin in serum. Hence, although subnormal values of lipase and immunoreactive trypsin are satisfactory indicators of pancreatic hypofunction, supranormal concentrations are not necessarily associated with the absence of malabsorption.
The observation that pancreatic enzyme activity may be greatly raised in the absence of acute pancreatitis in some patients with cystic fibrosis (three out of 23 in this study) remains intriguing. We have observed similar enzyme concentrations in 3-thalassaemia with iron overload.5 After our initial studies on immunoreactive trypsin in cystic fibrosis we thought that the raised concentrations of immunoreactive trypsin could be caused by a leak of the proenzyme from the damaged pancreatic acinar tissue into the circulation; this hypothesis was based on the fact that the radioimmunoassay of trypsin measures both trypsin and trypsinogen. We had not then expected that the raised immunoreactivity would be associated with an actual rise in enzyme activity. Our present results show that a leakage of enzymatic lipase from the pancreatic acini actually occurs.
As the amount of enzyme delivered by the pancreas into the duodenum in cystic fibrosis is negligible, it is not likely that any of the serum enzyme is derived through reabsorption from the gut. This challenges the concept that an appreciable proportion of pancreatic enzyme in circulation is derived through absorption from the gut.
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